<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">Relevant historical events that led to the eventual regulation of medicinal products, including drugs, biologics, and vaccines, include the following: the Biologics Control Act of 1902, which established the concepts of tolerability, purity, and potency standards for biologics
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref>; the Pure Food and Drug Act of 1906, which established the concepts of adulteration and misbranding of drugs
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref>; the Food, Drug, and Cosmetic Act of 1938, which created a safety standard for drugs that must be met prior to entering the market and which also developed the concepts of the Investigational New Drug exemption (IND) and the New Drug Application (NDA)
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref>; and the Kefauver-Harris Drug Amendments of 1962, which established an efficacy standard for drugs that must be met prior to entering the market.
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref> Important populations of patients that have been specifically addressed through statutes and enabling regulations include patients with orphan diseases
 <xref rid="bib5" ref-type="bibr">
  <sup>5</sup>
 </xref> and children.
 <xref rid="bib6" ref-type="bibr">
  <sup>6</sup>
 </xref>
</p>
